SZShiyuan Zhang

Shiyuan Zhang

*This is an algorithmically generated author record based on publicly available information.

Shiyuan Zhang has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dual transfusion independence and spleen volume reduction are associated with overall survival in patients with myelofibrosis treated with momelotinib: post hoc analyses of SIMPLIFY-1 and MOMENTUM

    by Francesca Palandri, Nicolaas P. M. Schaap, Jérôme Rey, Nikolas von Bubnoff, Andreas Reiter, Juan Carlos Hernández-Boluda, Timothy Devos, Bethan Psaila, Donal P. McLornan, Catherine Ellis, et al.

    Spleen volume reduction (SVR) and transfusion independence (TI) are associated with improved overall survival (OS) in myelofibrosis, but the joint contribution of these endpoints remains unclear. These post hoc analyses evaluated the association between concurrent SVR and TI at week 24 with OS in patients with primary or post–polycythemia vera/essential thrombocythemia myelofibrosis treated with momelotinib in the phase 3 SIMPLIFY‑1 (JAK inhibitor–naive) and MOMENTUM (JAK inhibitor–experienced) trials. Dual response was defined as joint TI and SVR thresholds of ≥ 35%, ≥ 25%, ≥ 15%, or ≥ 10% from baseline at week 24. Dual SVR + TI responders consistently demonstrated numerically longer OS vs. nonresponders across SVR thresholds. In SIMPLIFY‑1, hazard ratios (HRs) for death ranged from 0.26 (SVR10 + TI, 95% CI 0.16–0.43) to 0.64 (SVR35 + TI, 95% CI 0.38–1.10), with median OS exceeding that of nonresponders (e.g., 120.8 vs. 41.5 months for SVR10 + TI). In MOMENTUM, dual responders similarly showed numerically improved OS, with HRs of 0.33 (SVR10 + TI, 95% CI 0.17–0.65) and 0.32 (SVR35 + TI, 95% CI 0.11–0.88), with median OS not reached in responders (for both SVR10 + TI and SVR35 + TI) vs. 28.7 (nonresponders of SVR10 + TI) or 32.0 months (nonresponders of SVR35 + TI). Patients with both TI and SVR at week 24 demonstrated longer OS across all SVR thresholds evaluated, with the most pronounced separation of survival curves observed at the lowest SVR thresholds (≥ 10% and ≥ 15%). This pattern supports the concept that, in patients treated with momelotinib who achieve or maintain TI, relatively modest SVRs may be sufficient to achieve a survival advantage.

  • Open Access

    Perceived and experienced impacts of anemia and transfusion dependence in myelofibrosis: a mixed-methods study

    by Anna Cardellino, Hannah Collacott, Shiyuan Zhang, Vicky Turner, Kelesitse Phiri, Ned Weinshenker, Ruth Fein Revell, Dwaipayan Patnaik, Valentín García-Gutiérrez, Thomas W. LeBlanc, et al.

    Background: Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, splenomegaly, and debilitating symptoms. Anemia, present in approximately 35% of patients at diagnosis, often worsens over time and is associated with poor quality of life and worsened survival outcomes. Red blood cell transfusions help to manage anemia but are burdensome and may lead to iron overload. Existing literature focuses on clinical outcomes, and little is known about patient-perceived and -experienced impacts of transfusion and anemia. Methods: This mixed-methods study across 6 countries included qualitative interviews and an online survey of symptomatic (Myelofibrosis Symptom Assessment Form v4.0 Total Symptom Score ≥ 10) adults with MF with prior Janus kinase inhibitor experience, including both transfusion-dependent (TD) and transfusion-independent (TI) patients. Twenty participants (5 TD, 15 TI) completed interviews to inform an online survey fielded among 155 (76 TD, 51 TI, 28 transfusion-naive) participants. Questions assessed perceived and experienced burdens and impacts of anemia and transfusions. Results: Concept elicitation interviews ( N = 20) identified safety (85%), convenience (85%), and travel requirements (60%) as top concerns associated with transfusions; 40% noted symptom relief from transfusions, and 90% valued treatments to control anemia and reduce transfusion need. Across online survey participants ( N = 155), fatigue (85.2%), weakness (72.9%), and headaches (47.7%) were the most frequently reported symptoms, with negative impacts to daily activities (73%), physical activities (56%), ability to think (54%), and emotional health (53%). Transfusion-related inconveniences included time spent at the clinic (81%), travel time (40%), and scheduling issues (32%). The most burdensome impacts of transfusions were to daily activities (55.5%), emotional health (52.3%), and family responsibilities (35.5%). Among TD participants, 52.2% rated reducing their needed transfusion frequency as “extremely important,” although some acknowledged benefits associated with symptom relief. Conclusions: This study underscores the significant symptom burden of anemia and the broad impacts of transfusion dependence in MF. Qualitative and quantitative findings reveal emotional, physical, and logistical challenges associated with transfusions and patients’ strong desire to minimize their frequency. Results support the development of patient-centered therapies that improve anemia and reduce transfusions, addressing key medical needs in MF management.

  • Open Access

    Myelofibrosis and anemia: a German claims data analysis to describe treatment sequencing, survival outcomes, and healthcare resource utilization

    by Alexander Slowley, Tim D’EStrubé, Konstantin Neukirch, Scarlette Kienzle, Sophia Junker, Shiyuan Zhang, Thomas Wilke, Joachim R. Göthert

    Anemia presents a challenge in the management of myelofibrosis (MF). This symptom may be present at diagnosis or develop soon after, and around half of patients with MF require red blood cell transfusions within the first year. Progression to being transfusion dependent (TD) negatively affects prognosis and quality of life. This retrospective cohort study examined treatment sequencing from MF diagnosis, and overall survival (OS) and healthcare resource utilization (HCRU) from diagnosis and by transfusion status in newly diagnosed patients with MF in Germany. Data from 2010 to 2022 were collected from the AOK PLUS statutory health insurance fund database. Transfusion status was determined during a 180-day landmark period following first anemia treatment; patients were transfusion independent (TI) if they had received no transfusion, TD if they received ≥ 3 transfusions within 12 weeks, and transfusion requiring (TR) if they received transfusions but did not meet TD criteria during the landmark period. Of 555 patients assessed for treatment sequencing, only 41.8% received MF therapies (Janus kinase [JAK] inhibitors, peginterferon alpha-2a, immunomodulators, hydroxycarbamide, allogeneic hematopoietic stem cell transplantation), while 69.0% received anemia-directed interventions (59.8% being blood transfusions). Among patients receiving treatment for anemia ( n = 233), transfusion need was associated with shorter median OS (TD: 14.9, TR: 33.3, and TI: 74.3 months after the landmark period) and higher HCRU burden. This study documented high clinical and economic burden of anemia in patients with MF within Germany, particularly among TD patients, highlighting the need for novel treatments providing better prevention of anemia in MF.

  • Open Access

    Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison

    by Francesca Palandri, Venediktos Kapetanakis, Balázs Dobi, Massimo Breccia, Giuseppe A. Palumbo, Elisabetta Abruzzese, Massimiliano Bonifacio, Mario Tiribelli, Elena Maria Elli, Erika Morsia, et al.

    The Janus kinase (JAK) inhibitor ruxolitinib is a standard first-line therapy for patients with symptomatic and/or intermediate- to high-risk myelofibrosis (MF). However, the majority of patients discontinue ruxolitinib within 5 years of initiation, mainly due to lack or loss of response and/or therapy-related cytopenias. Additional treatments are needed to improve long-term outcomes, including overall survival (OS). Momelotinib, a JAK1/JAK2/activin A receptor type 1 inhibitor, has demonstrated benefits in reducing anemia and improving symptoms and spleen size in 3 phase 3 trials of patients with intermediate- to high-risk MF (SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM). These studies also provide data on patients who received momelotinib after discontinuing ruxolitinib. In the absence of long-term head-to-head comparisons of momelotinib and other treatments after discontinuation of ruxolitinib, the present study compared OS in patients with ruxolitinib-experienced MF from the momelotinib phase 3 trials vs. those treated with best available therapy (BAT) after ruxolitinib from the RUX-MF retrospective real-world study. The comparison was performed using an unanchored matching-adjusted indirect comparison (MAIC). Additionally, an MAIC of OS was conducted in an anemic subgroup (hemoglobin < 10 g/dL). After adjustment for cross-trial differences, the MAIC results showed a favorable trend for momelotinib vs. BAT, both in the overall population and in the anemic subgroup, with hazard ratios < 1 across all analytical scenarios and all population-matching models with an effective sample size of ≥ 20. This study is a key addition to current evidence surrounding OS post ruxolitinib and highlights the benefit of momelotinib in this setting.


  • Open Access

    Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis

    by Tom Liu, Mirko Fillbrunn, Shiyuan Zhang, Jingyi Chen, Weilong Li, Julia Platt, Nicole Niehoff, Gautam Sajeev, James Signorovitch

    Anemia affects many patients with myelofibrosis and is associated with poor prognosis. The Janus kinase inhibitor ruxolitinib is often used in myelofibrosis but may cause or worsen anemia. Using healthcare claims data from the IQVIA PharMetrics Plus database, this retrospective analysis evaluated healthcare resource utilization (HCRU), healthcare costs, and treatment patterns in ruxolitinib-treated patients with myelofibrosis stratified by anemia diagnosis prior to ruxolitinib initiation. Of 11,499 patients diagnosed with myelofibrosis between January 2011 and December 2022, 481 had ≥ 1 ruxolitinib claim on or after the myelofibrosis diagnosis date and were included in this analysis. Mean follow-up was 2.0 years. At baseline, anemic patients (n = 257) were older (mean age, 60.2 vs. 56.8 years; P < 0.001) and had a higher mean Charlson Comorbidity Index (1.0 vs. 0.5; P < 0.001) than nonanemic patients (n = 224). During follow-up, anemic patients exhibited higher median annual all-cause HCRU (inpatient admissions, 0.3 vs. 0.0 [P < 0.001]; outpatient visits, 40.0 vs. 20.0 [P < 0.001]; emergency department visits, 0.4 vs. 0.0 [P < 0.010]) and also had numerically higher median annual all-cause total healthcare costs ($198,491 vs. $170,419; P = 0.549) and medical costs ($44,830 vs. $12,017; P = 0.638) but significantly lower median annual total pharmacy costs ($129,381 vs. $136,686; P < 0.050), compared with nonanemic patients. Ruxolitinib discontinuation rates were higher and median time to discontinuation was approximately 1 year earlier in anemic patients (14.1 vs. 23.8 months; P < 0.010). In conclusion, patients with myelofibrosis and baseline anemia who are treated with ruxolitinib may be an HCRU-intensive population, suggesting a potential need for alternative treatments that reduce their medical resource burden.


  • Open Access

    Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists

    by Shiyuan Zhang, Alexandrosz Czira, Julia Harley, Kieran J. Rothnie, Lauren Lee, Mark Small

    Inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as maintenance-only or MART are limited. This study characterized clinical, economic, and humanistic burdens of asthma in Canada, China, Europe, Japan, and the US, using data collected from patients and physicians via a cross-sectional survey (Asthma Disease Specific Programme). Patients were ≥18 years of age with physician-confirmed asthma and receiving fixed-dose ICS/LABA for ≥3 months. Mean physician-reported symptom-free days over the past 30 days ranged from 10.1–20.6 days, and 31.5–34.6% of ICS/LABA users self-reported not well-controlled asthma. SABA co-prescription was reported in 8.8–67.8% of patients. These findings highlight the continued disease burden among ICS/LABA users, with the high level of SABA co-prescription indicating potentially inappropriate prescribing of ICS/LABA as MART or detrimental reliance on SABA medication in addition to MART.


  • Open Access

    Correction to: Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

    by Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J. Rothnie, Claire Trennery, Liza Yuanita, et al.

  • Open Access

    Correction to: Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

    by Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J. Rothnie, Claire Trennery, Liza Yuanita, et al.


  • Open Access

    Burden of illness among patients with asthma prescribed inhaled corticosteroids/long-acting β2-agonists

    by Shiyuan Zhang, Alexandrosz Czira, Julia Harley, Kieran Rothnie, Lauren Lee, Mark Small

    Inhaled corticosteroids (ICS) plus long-acting β2-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS/LABA as maintenance-only or MART are limited. This study characterized clinical, economic, and humanistic burdens of asthma in Canada, China, Europe, Japan, and the US, using data collected from patients and physicians via a cross-sectional survey (Asthma Disease Specific Programme). Patients were ≥18 years of age with physician-confirmed asthma and receiving fixed-dose ICS/LABA for ≥3 months. Mean physician-reported symptom-free days over the past 30 days ranged from 10.1–20.6 days, and 31.5–34.6% of ICS/LABA users self-reported not well-controlled asthma. SABA co-prescription was reported in 8.8–67.8% of patients. These findings highlight the continued disease burden among ICS/LABA users, with the high level of SABA co-prescription indicating potentially inappropriate prescribing of ICS/LABA as MART or detrimental reliance on SABA medication in addition to MART.

  • Open Access

    Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

    by Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J. Rothnie, Claire Trennery, Liza Yuanita, et al.

    Introduction There is limited information regarding multidimensional relationships between asthma control and health-related quality of life (HRQoL), work productivity, and asthma symptom burden in Japan. Furthermore, systematic qualitative investigations about asthma burden have not been performed. Methods This cross-sectional, mixed-methods study included Japanese patients (≥ 20 years) with asthma adherent to inhaled corticosteroids/long-acting β2-agonists (ICS/LABA). The primary endpoint was impact of asthma on HRQoL, measured using the Asthma Health Questionnaire-33 (AHQ-33). Secondary endpoints were cough burden (Japanese-adapted Leicester Cough Questionnaire [J-LCQ]) and impact of asthma on work/activities (asthma-specific Work Productivity and Activity Impairment Questionnaire [WPAI:Asthma]). Quantitative data were assessed for the overall population and for well-controlled (WC) and not well-controlled (NWC) asthma subgroups. Qualitative verbal interviews further assessed the impact of NWC asthma on patients’ HRQoL; emergent themes were extracted using thematic analyses. Results Of 454 patients, 45.2% (n = 205) had NWC asthma. Patients with NWC asthma had significantly worse asthma- and cough-related HRQoL across all AHQ-33 and J-LCQ domains and significantly greater work and activity impairment versus patients with WC asthma, across all assessed WPAI:Asthma domains. AHQ-33 total score was highly correlated with J-LCQ total and domain scores (r = − 0.8132 to r = − 0.7407). Nine themes emerged from qualitative interviews and confirmed that patients with NWC asthma had considerable HRQoL impairment due to asthma symptoms. Conclusions Patients with NWC asthma had higher symptom burden and worse HRQoL than patients with WC asthma, despite ICS/LABA adherence. Cough burden correlated with HRQoL, suggesting cough may be one of the key markers to inform treatment strategy for patients with asthma.